Steven J Mottola
Examiner (ID: 17760, Phone: (571)272-1766 , Office: P/2842 )
Most Active Art Unit | 2817 |
Art Unit(s) | 2515, 2842, 2843, 2817, 2502, 2607, 3621 |
Total Applications | 3603 |
Issued Applications | 3334 |
Pending Applications | 99 |
Abandoned Applications | 170 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18902982
[patent_doc_number] => 20240018467
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/371959
[patent_app_country] => US
[patent_app_date] => 2023-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14373
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18371959
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/371959 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | Sep 21, 2023 | Pending |
Array
(
[id] => 18903036
[patent_doc_number] => 20240018521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => COMPOSITIONS AND METHODS COMPRISING ENGINEERED SHORT NUCLEAR RNA (SNRNA)
[patent_app_type] => utility
[patent_app_number] => 18/447651
[patent_app_country] => US
[patent_app_date] => 2023-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25298
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18447651
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/447651 | COMPOSITIONS AND METHODS COMPRISING ENGINEERED SHORT NUCLEAR RNA (SNRNA) | Aug 9, 2023 | Pending |
Array
(
[id] => 18724310
[patent_doc_number] => 20230338445
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/322961
[patent_app_country] => US
[patent_app_date] => 2023-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20751
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322961
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/322961 | Oncolytic viruses for modified MHC expression | May 23, 2023 | Issued |
Array
(
[id] => 18565714
[patent_doc_number] => 20230256041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
[patent_app_type] => utility
[patent_app_number] => 18/105374
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18105374
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/105374 | Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling | Feb 2, 2023 | Pending |
Array
(
[id] => 18626740
[patent_doc_number] => 20230285546
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => COMPOSITIONS COMPRISING ALPHA-FACTOR PREPRO SEQUENCE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/093805
[patent_app_country] => US
[patent_app_date] => 2023-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28319
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18093805
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/093805 | COMPOSITIONS COMPRISING ALPHA-FACTOR PREPRO SEQUENCE AND USES THEREOF | Jan 4, 2023 | Pending |
Array
(
[id] => 19256864
[patent_doc_number] => 12016893
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-25
[patent_title] => Oncolytic viruses for modified MHC expression
[patent_app_type] => utility
[patent_app_number] => 18/080253
[patent_app_country] => US
[patent_app_date] => 2022-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 20136
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18080253
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/080253 | Oncolytic viruses for modified MHC expression | Dec 12, 2022 | Issued |
Array
(
[id] => 18724307
[patent_doc_number] => 20230338442
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => AAV-Mediated Gene Transfer for Retinopathy
[patent_app_type] => utility
[patent_app_number] => 18/079749
[patent_app_country] => US
[patent_app_date] => 2022-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43026
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18079749
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/079749 | AAV-Mediated Gene Transfer for Retinopathy | Dec 11, 2022 | Pending |
Array
(
[id] => 18485212
[patent_doc_number] => 20230212541
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/052801
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052801
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052801 | Gene editing systems comprising an RNA guide targeting hydroxyacid oxidase 1 (HAO1) and uses thereof | Nov 3, 2022 | Issued |
Array
(
[id] => 18225202
[patent_doc_number] => 20230064196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
[patent_app_type] => utility
[patent_app_number] => 17/964465
[patent_app_country] => US
[patent_app_date] => 2022-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29250
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17964465
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/964465 | Genetically modified non-human animals with humanized immunoglobulin locus | Oct 11, 2022 | Issued |
Array
(
[id] => 18374379
[patent_doc_number] => 20230149458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/846868
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 138999
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846868
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846868 | Articles of manufacture and methods for treatment using adoptive cell therapy | Jun 21, 2022 | Issued |
Array
(
[id] => 18050714
[patent_doc_number] => 11524081
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-13
[patent_title] => Codon optimized REP1 genes and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/740045
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 16377
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740045
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/740045 | Codon optimized REP1 genes and uses thereof | May 8, 2022 | Issued |
Array
(
[id] => 18526352
[patent_doc_number] => 11713337
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-01
[patent_title] => Peptide, compositions and method for delivery of agents into cells and tissues
[patent_app_type] => utility
[patent_app_number] => 17/646496
[patent_app_country] => US
[patent_app_date] => 2021-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 50
[patent_figures_cnt] => 24
[patent_no_of_words] => 21775
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17646496
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/646496 | Peptide, compositions and method for delivery of agents into cells and tissues | Dec 29, 2021 | Issued |
Array
(
[id] => 17441933
[patent_doc_number] => 20220062438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => CODON OPTIMIZED REP1 GENES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/463262
[patent_app_country] => US
[patent_app_date] => 2021-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16359
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463262
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/463262 | Codon optimized REP1 genes and uses thereof | Aug 30, 2021 | Issued |
Array
(
[id] => 17385607
[patent_doc_number] => 20220033459
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => Chimeric T Cell Receptors, Nucleic Acids, And Methods Of Making And Using The Same
[patent_app_type] => utility
[patent_app_number] => 17/387347
[patent_app_country] => US
[patent_app_date] => 2021-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10397
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387347
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/387347 | Chimeric T Cell Receptors, Nucleic Acids, And Methods Of Making And Using The Same | Jul 27, 2021 | Pending |
Array
(
[id] => 17170738
[patent_doc_number] => 20210324408
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM AMYELOIS
[patent_app_type] => utility
[patent_app_number] => 17/339597
[patent_app_country] => US
[patent_app_date] => 2021-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30672
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339597
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/339597 | Transposition of nucleic acid constructs into eukaryotic genomes with a transposase from amyelois | Jun 3, 2021 | Issued |
Array
(
[id] => 18005346
[patent_doc_number] => 20220364112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => ONCOLYTIC VIRUS FOR TREATING BRAIN TUMORS USING RECOMBINANT NEWCASTLE DISEASE VIRUS INTO WHICH NEWCASTLE DISEASE VIRUS VECTOR-BASED PTEN GENE IS INSERTED AND COMPOSITION FOR TREATING BRAIN TUMORS USING SAME
[patent_app_type] => utility
[patent_app_number] => 17/616762
[patent_app_country] => US
[patent_app_date] => 2021-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9733
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616762
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/616762 | Oncolytic virus for treating brain tumors using recombinant Newcastle disease virus into which Newcastle disease virus vector-based PTEN gene is inserted and composition for treating brain tumors using same | Jun 2, 2021 | Issued |
Array
(
[id] => 17532406
[patent_doc_number] => 20220111015
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-14
[patent_title] => TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/328705
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328705
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/328705 | TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS | May 23, 2021 | Pending |
Array
(
[id] => 17082417
[patent_doc_number] => 20210277423
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 17/327625
[patent_app_country] => US
[patent_app_date] => 2021-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68041
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327625
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/327625 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | May 20, 2021 | Pending |
Array
(
[id] => 17156425
[patent_doc_number] => 20210317476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => FOWL ADENOVIRUS 9 (FADV-9) VECTOR SYSTEM AND ASSOCIATED METHODS
[patent_app_type] => utility
[patent_app_number] => 17/244079
[patent_app_country] => US
[patent_app_date] => 2021-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16115
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244079
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/244079 | FOWL ADENOVIRUS 9 (FADV-9) VECTOR SYSTEM AND ASSOCIATED METHODS | Apr 28, 2021 | Pending |
Array
(
[id] => 17037140
[patent_doc_number] => 20210254098
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => POLYEPITOPE CONSTRUCTS FOR USE IN IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/241546
[patent_app_country] => US
[patent_app_date] => 2021-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9061
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241546
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/241546 | POLYEPITOPE CONSTRUCTS FOR USE IN IMMUNOTHERAPY | Apr 26, 2021 | Pending |